AUS
NZ
UK
CA
USA
IND
Highlights
- Chemed’s stock hits a 52-week low of $517.44, down 1.1%.
- Company missed analysts’ earnings expectations for the latest quarter.
- Dividend payout maintained with a 0.39% yield, reflecting the company’s stability.
Chemed Corp recently hit a new 52-week low, sparking concerns among shareholders. Despite increasing revenue, the company missed earnings estimates, causing its stock to drop by 1.1%. As part of the NYSE Healthcare Stocks, Chemed remains a key player in hospice care and plumbing services, but its recent financial struggles raise questions about its performance moving forward.
Chemed Hits New Low Amid Earnings Miss and Ongoing Challenges
Chemed Corporation (NYSE:CHE) recently saw its stock price drop to a new 52-week low, sparking concerns among shareholders and analysts alike. On Tuesday, Chemed traded as low as $512.12, and despite some minor recovery, the stock closed at $517.44. This decline marks a 1.1% drop in stock value, continuing the downward trend that has concerned those monitoring healthcare stocks.
Disappointing Earnings Results
Chemed’s recent earnings report, released in late October, highlighted its challenges. The company reported earnings per share (EPS) of $5.64, falling short of analysts’ expectations of $5.76. This 0.12 difference was significant enough to cause concern. Revenue for the quarter also missed projections, amounting to $606.18 million compared to the expected $612.22 million. However, despite these misses, Chemed’s revenue still showed a 7.4% increase compared to the same period last year, signaling the potential for long-term growth despite short-term challenges.
Dividend Stability Amid Challenges
In a sign of stability, Chemed continues to uphold its dividend payouts. The company declared a quarterly dividend of $0.50 per share, paid in December, with an annualized yield of 0.39%. This move demonstrates the company’s commitment to maintaining shareholder value even in challenging times, despite its recent earnings miss and stock decline.
Institutional Investment Activity
Chemed continues to attract institutional investors, which account for nearly 96% of the company’s shares. Notable hedge funds such as Bank of New York Mellon and Allspring Global Investments have increased their positions in Chemed, signaling confidence in the company’s long-term prospects. These institutional movements suggest that larger market players still believe in Chemed’s potential, despite recent stock performance.
Chemed’s Business Segments
Chemed operates two key business segments: VITAS and Roto-Rooter. The VITAS segment provides hospice and palliative care services to patients, offering a wide range of healthcare services. On the other hand, Roto-Rooter provides plumbing, water restoration, and related services to residential and commercial customers. This diversification allows Chemed to maintain a steady income stream, though recent market volatility has still impacted its stock.
Chemed’s Debt and Cash Flow Situation
Despite the company’s strong market capitalization of $7.79 billion, it faces some liquidity concerns. With a profit to earning ratio of 26.15 and a price-to-earnings growth ratio. of 2.32, Chemed’s debt and earnings reports may affect market sentiment. For now, however, Chemed’s management is focused on maintaining operations and dividends while navigating the financial hurdles ahead.
